Benzinga | Dec 16, 2021 08:07AM EST

Cowen & Co. Initiates Coverage On NeoGenomics with Outperform Rating, Announces Price Target of $42

Cowen & Co. analyst Dan Brennan initiates coverage on NeoGenomics (NASDAQ:NEO) with a Outperform rating and announces Price Target of $42.